Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8+ T cells in Breast Cancer Implications for Adoptive Cell Therapy.
Grace Ivonne GattasGregory NoëlFrancisco Carlos López MárquezFaviel Francisco González-GalarzaAdria Prieto-HinojosaLydia Enith Nava-RiveraKaren Willard-GalloJesus R ArgüelloPublished in: Current pharmaceutical biotechnology (2023)
Evidence from our study suggests that CD8 TILs present in the stroma of luminal A and luminal B breast cancer patients can be quantified and phenotyped by flow cytometry and be further expanded ex vivo. The immuno-phenotyping of these markers may be targeted to improve the success of immunotherapeutic approaches, such as adoptive cellular therapy (ACT) in patients with BC.